Tilray: Haywood Reiterates Hold Rating, $16.50 Price Target

With the Aphria, Tilray (NASDAQ: TLRY) merger finalized and Aphria shares consolidated earlier this month, many analysts are now updating their models, price targets, and ratings. Tilray now has 18 analysts covering the combined company with a weighted 12-month price target of U$19.75. Alliance Global has the street high with a U$32 price target and the lowest comes from GLJ Research with a U$1.27 price target. Two analysts have strong buy and buy ratings. 13 analysts have hold rating and one analyst has a sell rating.

In Haywoods note issued on May 18th, their analyst Neal Gilmer reiterates their hold rating and U$16.50 price target, saying this merger creates a clear leader in the Canadian market with significant European and U.S exposure.

For the Canadian assets, Gilmer believes that the company is now a leader in the space, with the idea that the company could potentially reach 25-30% of total market share. The combined company now has a bunch of different brands, ranging from a variety of different categories. Gilmer believes that they will be able to be a “profitable leader in Canada.”

For international, Gilmer likes the combination of CC Pharma and Tilray’s 2.7 million sq feet facility in Portugal which can serve as a low-cost producer for the medical markets.

Cambria Gold Mines — sponsored Sponsored · Cambria Gold Mines

Gilmer ends the note by saying that Tilray has now, “distinguished itself among its peer group,” and they are encouraged by the international opportunity and U.S optionality. But he is somewhat cautious of how their main market, Canadian cannabis, remains and believes that there will be prolonged COVID-19 headwinds.

Below you can see the consolidated 2021-2023 estimates.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Is Agnico Eagle Seabridge Gold’s Mystery Lender?

This Gold Giant Is Building 1.5 Million More Ounces a Year | Agnico Eagle Q3 Earnings

This Gold Giant Was a Mess. Now It’s Back! | Barrick Mining Q3 2026 Earnings

Recommended

Epic Gold Delivers Maiden 279,000 Ounce Inferred Resource at Wilson Project

First Phosphate Adds UK Export Finance to Growing Export Credit Lineup With C$220 Million Letter of Interest

Related News

Curaleaf: Canaccord Reiterates $22 Price Target Following Secured Note Issuance

On December 16th, Curaleaf Holdings (CSE: CURA) announced the closing of US$425 million 8% senior...

Thursday, December 30, 2021, 04:38:00 PM

Bright Minds: Eight Capital Assigns $11.50 Price Target To Firm

Last week, Eight Capital launched coverage on a basket of psychedelic companies. This comes after...

Monday, September 20, 2021, 10:09:00 AM

CloudMD: Canaccord Reiterates $3.25 Price Target Following Acquisition

This morning, CloudMD Software & Services (TSXV: DOC) announced that they purchased Rx Infinity, an...

Wednesday, January 27, 2021, 04:01:00 PM

Illustrated: Cannabis Earnings Week for the Third Quarter of 2019

This past week, as many are aware, was the week of cannabis earnings season. The...

Saturday, November 16, 2019, 08:00:23 AM

US Cannabis: Stifel Expects Growth To Decelerate In Q4 Earnings

On February 2nd, Stifel-GMP put out their fourth quarter 2021 earnings preview, calling it “The...

Wednesday, February 9, 2022, 04:33:00 PM